![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
Physostigmine was administered orally 1 mg q.i.d. for one month to 8 patients with a clinical diagnosis of Alzheimer's presenile dementia. The possible beneficial effects of the drug were evaluated by means of a neuropsychological battery administered to all patients before and after treatment. The performances obtained by demented patients on vetest did not show any difference in comparison with performances obtained on the first neuropsychologic assessment. Some implications of these negative results are briefly discussed.
Additional information
Notes on contributors
G. Gainotti
Joyce Laing works in the Department of Child and Family Psychiatry, Playfield House, Cupar, Fife, and is a Consultant Art Therapist to Psychiatric Hospitals and Prisons and Chairwoman of the Scottish Society of Art and Psychology.
C. Masullo
Joyce Laing works in the Department of Child and Family Psychiatry, Playfield House, Cupar, Fife, and is a Consultant Art Therapist to Psychiatric Hospitals and Prisons and Chairwoman of the Scottish Society of Art and Psychology.